We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+13.27%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.42B
AUM Growth
-$150M
Cap. Flow
-$442M
Cap. Flow %
-12.92%
Top 10 Hldgs %
65.01%
Holding
63
New
3
Increased
6
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
FDMT icon
4D Molecular Therapeutics
FDMT
+$57.4M
2
XNCR icon
Xencor
XNCR
+$16M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.97M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$9.39M
5
AXSM icon
Axsome Therapeutics
AXSM
+$7.94M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$109M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$80.7M
3
MRUS
Merus
MRUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$59.4M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TENX icon
51
Tenax Therapeutics
TENX
$389M
$1.17M 0.03%
+339,549
New +$1.23M
ENGNW icon
52
enGene Therapeutics Warrants
ENGNW
$3.64M
$804K 0.02%
945,402
– –
MTEM
53
DELISTED
Molecular Templates, Inc.
MTEM
$734K 0.02%
522,238
– –
NCEL
54
NewcelX Ltd
NCEL
$18.5M
$728K 0.02%
14,368
– –
FBRX icon
55
Forte Biosciences
FBRX
$1.57B
$668K 0.02%
119,282
-2
-0% -$21
JANX icon
56
Janux Therapeutics
JANX
$920M
– –
-441,528
Closed -$18.5M
MRUS
57
DELISTED
Merus
MRUS
– –
-1,279,049
Closed -$75.7M
ROIV icon
58
Roivant Sciences
ROIV
$24.4B
– –
-2,742,409
Closed -$29M
RZLT icon
59
Rezolute
RZLT
$449M
– –
-190,815
Closed -$821K
UNCY icon
60
Unicycive Therapeutics
UNCY
$138M
– –
-220,000
Closed -$1.1M
VIRX
61
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-3,614,662
Closed -$1.97M
CALT
62
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
– –
-750,000
Closed -$29.2M
ASLN
63
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-131,250
Closed -$315K
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2024 Portfolio in Review

As of Q3 2024, BVF Inc held 63 positions worth $3.42B, down 4.2% from $3.57B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

BVF Inc withdrew a net $442M in Q3 2024, closing 8 positions and reducing 10 holdings. Its most notable exit was Merus, an estimated $75.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Xencor worth $17.1M.

  • BVF Inc's largest Q3 2024 buy was Xencor: 850,000 shares worth $17.1M.
  • BVF Inc added most to 4D Molecular Therapeutics in Q3 2024, an estimated $57.4M increase.
  • BVF Inc's biggest Q3 2024 reduction was Revolution Medicines, cutting an estimated $109M.
  • BVF Inc fully exited Merus in Q3 2024, selling an estimated $75.7M.
  • BVF Inc's ten largest holdings make up 65% of its $3.42B portfolio in Q3 2024.
  • BVF Inc opened 3 new positions and closed 8 in Q3 2024.
  • BVF Inc's portfolio value fell 4.2% quarter-over-quarter to $3.42B.

Based on BVF Inc's 13F filing for Q3 2024, filed 14 Nov 2024.